Frontlight ResearchEarly access
TerminatedNo phase
MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women
Key facts
- Who runs it
- Public Health Foundation Enterprises, Inc.
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 2 people enrolled
- Started
- 18 Mar 2023
- Ended
- 21 Mar 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- MyPrEP Plus Package
- Standard of Care (SOC)
- Record updated
- 28 August 2025
- Why it stopped
- Recruitment was halted prematurely as a result of the termination of the grant by the NIH.
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Can take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Are age 18 or older
- Identify as a transgender woman or woman and was assigned male sex at birth
- Are not currently on PrEP in the last three months and interested in learning more about PrEP
- Able to successfully send and receive text messages
- HIV negative by self-report
- Are able to speak, read and write in English or Spanish
- Report any of the following in the last 12 months:; Having anal or vaginal sex with a person assigned male at birth; Exchange of sex for money, goods, or services; Received a diagnosis of a sexually transmitted infection; Sharing injection equipment
- Are able and willing to provide written informed consent and participate for the duration of the study
Who cannot take part
- In a mutually monogamous sexual relationship with an HIV-negative partner for the past 12 months
- Of any medical, psychiatric, or social condition that in the opinion of the investigator would preclude participation or their ability to remain in the trial
- Study site staff member
Where in United States
- Bridge HIV, San Francisco Department of Public HealthSan Francisco, United States
About the trial
What the trial wants to find out
The primary goal of this randomized controlled trial is to learn if a decision support tool called MyPrEP Plus can help transgender women make decisions about taking pre-exposure prophylaxis (PrEP) for HIV prevention.
The 2 groups in the trial
- Experimental Conditon: MyPrEP PlusTreatment being tested
The intervention administered in the experimental condition includes PrEP decisional and adherence support with the MyPrEP Plus package.
Treatment: MyPrEP Plus Package
- Control Condition: Standard of CareOther group
Participants randomized to the control condition will receive PrEP support through the standard of care.
Treatment: Standard of Care (SOC)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 28 August 2025